Back to Search Start Over

Glucagon kinetics assessed by mathematical modelling during oral glucose administration in people spanning from normal glucose tolerance to type 2 diabetes.

Authors :
Andreozzi F
Mancuso E
Rubino M
Salvatori B
Morettini M
Monea G
Göbl C
Mannino GC
Tura A
Source :
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Apr 12; Vol. 15, pp. 1376530. Date of Electronic Publication: 2024 Apr 12 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background/objectives: Glucagon is important in the maintenance of glucose homeostasis, with also effects on lipids. In this study, we aimed to apply a recently developed model of glucagon kinetics to determine the sensitivity of glucagon variations (especially, glucagon inhibition) to insulin levels ("alpha-cell insulin sensitivity"), during oral glucose administration.<br />Subjects/methods: We studied 50 participants (spanning from normal glucose tolerance to type 2 diabetes) undergoing frequently sampled 5-hr oral glucose tolerance test (OGTT). The alpha-cell insulin sensitivity and the glucagon kinetics were assessed by a mathematical model that we developed previously.<br />Results: The alpha-cell insulin sensitivity parameter (named S <subscript>GLUCA</subscript> ; "GLUCA": "glucagon") was remarkably variable among participants (CV=221%). S <subscript>GLUCA</subscript> was found inversely correlated with the mean glycemic values, as well as with 2-hr glycemia of the OGTT. When stratifying participants into two groups (normal glucose tolerance, NGT, N =28, and impaired glucose regulation/type 2 diabetes, IGR_T2D, N =22), we found that S <subscript>GLUCA</subscript> was lower in the latter (1.50 ± 0.50·10 <superscript>-2</superscript> vs . 0.26 ± 0.14·10 <superscript>-2</superscript> ng·L <superscript>-1</superscript> <subscript>GLUCA</subscript> /pmol·L <superscript>-1</superscript> <subscript>INS</subscript> , in NGT and IGR_T2D, respectively, p=0.009; "INS": "insulin").<br />Conclusions: The alpha-cell insulin sensitivity is highly variable among subjects, and it is different in groups at different glucose tolerance. This may be relevant for defining personalized treatment schemes, in terms of dietary prescriptions but also for treatments with glucagon-related agents.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Andreozzi, Mancuso, Rubino, Salvatori, Morettini, Monea, Göbl, Mannino and Tura.)

Details

Language :
English
ISSN :
1664-2392
Volume :
15
Database :
MEDLINE
Journal :
Frontiers in endocrinology
Publication Type :
Academic Journal
Accession number :
38681771
Full Text :
https://doi.org/10.3389/fendo.2024.1376530